Archeus Technologies and Wisconsin Alumni Research Foundation to Advance ART-101 into Clinical Development for Prostate Cancer
“With strong preclinical data supporting the continued development of ART-101, Archeus is eager to lead the evaluation of this novel candidate through first-in-human studies,” said Evan Sengbusch, Ph.D., chief executive officer of Archeus Technologies. “Leveraging our team’s proven experience ushering new radiopharmaceutical agents from concept through clinical translation, paired with our close collaboration with UW as a world-class radiopharmaceutical research organization, Archeus is uniquely positioned to progress ART-101 into the next stage of development. This asset adds to our Phase 1-ready portfolio of differentiated radiopharmaceutical therapies with the potential to provide curative responses to cancers that are particularly challenging to treat.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data